Loss of PIMREG impairs double-strand break signaling and repair
Maria Vitoria de Rizzo Gasparini, Laís do Carmo, Giovanna Goncalves de Almeida, Mariana Siqueira Lacerda Mamede, Isabela David Cardoso, Lígia Arantes Sardinha, Isabela Spido DiasiD, Jennifer Ann BlackiD, Vanessa Cristina ArfelliiD, Yun-Chien ChangiD, Elza Tiemi Sakamoto‐HojoiD, Stephanie Heinzlmeir, Bernhard KusteriD, Philipp A. GreifiD, Leticia Fröhlich ArchangeloiD
Abstract
Glioblastoma (GBM) is the most common primary brain tumor in adults. It is an aggressive type of tumor with an average overall survival of 12-15 months post-diagnosis. Standard treatment involves surgical resection, followed by radiotherapy and chemotherapy with temozolomide (TMZ). However, resistance to treatment is frequently observed. PIMREG is a marker of proliferation highly expressed across different tumor types, with particularly elevated levels in GBM. Our previous study revealed that PIMREG silencing sensitizes GBM cells to TMZ treatment and affects ATM activation, a key apical kinase involved in DNA damage signaling. Given the emerging significance of PIMREG in the DNA damage response, we sought to explore PIMREGs role in DNA damage repair and signaling in GBM cells exposed to genotoxic agents. Here we assessed the functionally enriched pathways associated with high PIMREG expression in GBM patient samples, analyzed the interactome of PIMREG upon treatment of GBM cells with TMZ and evaluated the impact of PIMREG loss on DNA damage signaling, DNA break formation and the repair of double-strand breaks. Our findings reveal that PIMREG functions as a direct substrate for ATM/ATR kinases, interacts with key DNA repair proteins upon TMZ treatment and actively facilitates the cellular response to chemotherapy- and radiotherapy-induced DNA damage. Taken together, PIMREG may function in the DNA damage response, particularly in the signaling and repair of double strand breaks via homologous recombination in GBM cells. In all, our data suggested high PIMREG expression may affect resistance of GBM cells to treatment.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 33%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma
H. Hermanowski, B. Huebert, … D. Quenet·bioRxiv·Jun 30, 2020
- Unlocking the potential of miR-19b in the regulation of temozolomide response in glioblastoma patients via targeting PPP2R5E, a subunit of the protein phosphatase 2A complex
E. Kashani, K. Hlavackova, … E. Vassella·bioRxiv·Jan 16, 2023
- PARP inhibitor counteracts Temozolomide Resistance in Glioblastoma Multiforme
Édouard Samarut, Gaston Tabourel, … Aurélien A. Sérandour·bioRxiv·Dec 13, 2024
- Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair Inhibition
I. C. Sorribes, S. K. Handelman, H. V. Jain·bioRxiv·Oct 5, 2019
- Acquisition and reversal of glioblastoma chemoresistance are mediated by the Rho GTPase pathway
Yuli Thamires Magalhães, Viktor Kalbermatter Boell, Fábio Luís Forti·Molecular Cancer TherapeuticsPeer-reviewed·Oct 28, 2025
- BRAT1 - a new therapeutic target for glioblastoma
Alicia Haydo, Jennifer Schmidt, … Benedikt Linder·Cellular and Molecular Life SciencesPeer-reviewed·Jan 20, 2025